C.R. Bard (NYSE:BCR) managed to close the books on a large chunk of patient complaints against its Avaulta mesh implant, settling more than 500 cases in its 2nd quarter.
The company didn't say just how much it settled for, but reported that it paid $259 million in total during the quarter to cover undefined "product liability matters."
Help employers find you! Check out all the jobs and post your resume.
